Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2000-08-15
2001-05-29
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S464000, C424S468000
Reexamination Certificate
active
06238699
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to an improvement in the treatment of Parkinson's disease and related disorders. More specifically, the present invention introduces novel formulations of the combination carbidopa and levodopa, the current mainstay of therapy.
2. Background and Prior Art
Parkinson's disease is associated with the depletion of dopamine from cells in the corpus striatum. Since dopamine does not cross the blood brain barrier and cannot therefore be used to treat Parkinson's disease, its immediate precursor, levodopa, is used instead because it penetrates the brain where it is decarboxylated to dopamine. But levodopa is also decarboxylated to dopamine in peripheral tissues and consequently only a small portion of administered levodopa is transported unchanged to the brain. This reaction can be blocked by carbidopa which inhibits decarboxylation of peripheral levodopa but cannot itself cross the blood brain barrier and has no effect on the metabolism of levodopa in the brain.
The combination of carbidopa and levodopa is considered to be the most effective treatment for symptoms of Parkinson's disease (The Medical Letter, 35:31-34, 1993). Nevertheless, certain limitations become apparent within two to five years of initiating combination therapy. As the disease progresses, the benefit from each dose becomes shorter (“the wearing off effect”) and some patients fluctuate unpredictably between mobility and immobility (“the on-off effect”). “On” periods are usually associated with high plasma levodopa concentrations and often include abnormal involuntary movements, i.e., dyskinesias. “Off” periods have been correlated with low plasma levodopa and bradykinetic episodes.
In an effort to reduce the occurrences of “wearing off” and “on-off” phenomena, a controlled release oral dosage combination was introduced with claims of slow and simultaneous release of carbidopa and levodopa from the formulation (U.S. Pat. No. 4,900,755 issued Feb. 13, 1990). Data from clinical trials cited in the patent indicate that effective anti-Parkinson effects were achieved with fewer daily doses of the controlled release form as compared with the conventional combination.
Nevertheless, there remains a significant flaw in the therapeutic application of controlled release carbidopa-levodopa; that is, the considerable delay in onset of action. Mean time to peak concentration in healthy elderly subjects was found to be two hours for controlled release carbidopa-levodopa and only 0.5 hours for the conventional form (Physicians Desk Ref.,
47
th Ed., p. 976, 1993). A controlled release dosage form that could also provide rapid onset of action, at least equivalent to that of conventional carbidopa-levodopa would have an obvious clinical advantage over current therapy.
The strategy proposed in the present invention is to formulate oral dosage forms containing both immediate release carbidopa-levodopa and controlled release carbidopa-levodopa. Ingestion would provide rapid onset anti-Parkinson activity via the immediate release component followed by sustained therapeutic activity from the controlled release component.
SUMMARY OF THE INVENTION
It is the purpose and principal object of this invention to provide an improved method for the treatment of Parkinson's disease by using novel formulations of the combination carbidopa-levodopa which a) are effective in preventing the symptoms of Parkinson's disease and yet which b) act rapidly, avoiding significant onset delay common to the standard controlled release therapy.
DETAILED DESCRIPTION
The novel oral dosage formulations of the present invention each contain immediate release and controlled release components of the anti-Parkinson agents carbidopa (5-200 mg) and levodopa (25-600 mg). The conventional immediate release combination of carbidopa-levodopa reaches peak plasma concentrations in 30 minutes, whereas the onset of the controlled release component is two hours followed by prolonged release over a four- to six-hour period.
The usual daily therapeutic dose of levodopa, when administered with carbidopa, is 300 to 750 mg and the dose of carbidopa approximately 75 mg per day but the latter is apparently devoid of adverse effects even at doses of 400 mg per day (J. E. Ahlskog, Hosp. Form., 27:146, 1992). Although the optimum daily dosage of carbidopa-levodopa must ultimately be determined by titrating each patient, a preferred range for twice daily maintenance therapy may include immediate release of 10-25 mg carbidopa and 50-200 mg levodopa and sustained release of 25-75 mg carbidopa and 100-400 mg levodopa.
Specific examples of these formulations are cited below. The amount and excipients listed can be changed through methods known to those skilled in the preparation of immediate and sustained release dosage forms. Some of these methods are available in Remington's Pharmaceutical Sciences, 17
th
Ed., 1985, a standard reference in the field.
REFERENCES:
patent: 4900755 (1990-02-01), Dempski et al.
patent: 5738874 (1998-04-01), Conte et al.
Various, Oral Solid Dosage Forms,Remington's Pharmaceutical Sciences, 17th Edition, Chapter 90, 1985.
Various, Coating of Pharmaceutical Dosage Forms,Remington's Pharmaceutical Sciences, 17th Edition, 1633, 1985.
Mark A. Longer and Joseph R. Robinson, PhD, Sustained-Release Drug Delivery Systems,Remington's Pharmaceutical Sciences, 17th Edition, 1644, 1985.
Various, Sinemet CR,Physician′ Desk Reference,976, 1993.
Various, Drugs for Parkinson's DiseaseThe Medicl Letter on Drugs and therapeutics, 35 (Issue 894), 31-34, Apr. 16, 1993.
Ahlskog, J. Eric, MD, PhD, Parkinson's Disease: Update on Pharmacologic Options to Slow Progression and Treat Symptons,Hosp. Formul., 27, 146-152, 161-163, Feb. 1992.
Fato Gildo E.
Page Thurman K.
Seidlech Brian
LandOfFree
Pharmaceutical formulations containing a combination of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical formulations containing a combination of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulations containing a combination of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2522137